FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

APPLE ROBERT F 		2. Issuer Name and Ticker or Trading Symbol

ANTARES PHARMA, INC. [ ATRS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
President & CEO
(Last)          (First)          (Middle)

C/O ANTARES PHARMA, INC., 100 PRINCETON SOUTH, SUITE 300 		3. Date of Earliest Transaction (MM/DD/YYYY)

2/22/2017
(Street)

EWING, NJ 08628
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   2/22/2017     A (1)    5612   A $0.00   895612   D    
Common Stock   2/22/2017     F (1)    1763   D $2.37   893849   D    
Common Stock   5/28/2017     F (2)    14903   D $2.51   878946   D    
Common Stock   5/29/2017     F (3)    3390   D $2.51   875556   D    
Common Stock   6/2/2017     F (4)    38034   D $2.57   837522   D    
Common Stock   6/7/2017     A    338115   (5) D $2.66   1175637   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $2.66   6/7/2017     A      725751   (6)        (7) 6/7/2027   Common Stock   725751   $0.00   725751   D    

Explanation of Responses:
(1)  On May 22, 2013, Mr. Apple was granted a performance stock unit award that was contingent upon the Company achieving certain performance goals over a three year performance period ended December 31, 2016. The shares reported here represent the total number of shares that were earned upon the achievement and certification of one of the performance goals, which was net settled. The shares disposed represents the shares withheld to settle tax liability in connection with the vesting of the performance stock unit award.
(2)  Represents shares withheld to settle tax liability in connection with the vesting of a restricted stock unit award that was previously granted on May 28, 2015.
(3)  Represents shares withheld to settle tax liability in connection with the vesting of a restricted stock unit award that was previously granted on May 29, 2014.
(4)  Represents shares withheld to settle tax liability in connection with the vesting of a restricted stock unit award that was previously granted on June 2, 2016.
(5)  Represents grant of restricted stock units made under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant.
(6)  Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan.
(7)  The options vest in equal quarterly installments over three years from the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
APPLE ROBERT F
C/O ANTARES PHARMA, INC.
100 PRINCETON SOUTH, SUITE 300
EWING, NJ 08628 		X
President & CEO

Signatures
/s/Keith Muckenhirn as attorney-in-fact for Robert F. Apple 6/9/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Antares Pharma Charts.
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Antares Pharma Charts.